burger

A pharmaceutical company
specialising in biological
medicinal products

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
3

Bioproduction sites in France

92/100

This is the professional gender equality index obtained by LFB

15 medicines

prescribed to

hospital

€ 400 M in turnover

in 2018

22

medical specialties that regularly use
LFB’s medicines

1 st in France

in the field
of plasma-derived
medicinal products

Meeting with

Denis DELVAL ,
Chairman and CEO of the LFB Group

" my ambition is to build the future of the Group with the men and women of the LFB. "

LFB completes the sale of CELLforCURE to Novartis

All news

2:11

LFB Group corporate film 2019

Living with peripheral neuropathies, a video supported by LFB

All videos

LFB completes the sale of CELLforCURE to Novartis

Discover the 2019 LFB corporate video

LFB strategic transformation project

CELLforCURE will produce innovative cancer CAR-T treatments for Novartis
Denis Delval pdg

Denis DELVAL is appointed CEO of LFB SA

The French State proposes Denis Delval as member of the Board in anticipation of his appointment as new LFB Group CEO
92/100

This is the professional gender equality index obtained by LFB
15 medicines

prescribed to

hospital
3

Bioproduction sites in France
1st in France

in the field
of plasma-derived
medicinal products

Living with peripheral neuropathies, a video supported by LFB

there is 12 months

2:11

LFB Group corporate film 2019

there is 4 years